<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "JATS-journalpublishing1.dtd">
<article xml:lang="KO" article-type="research-article">

<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Immune Netw</journal-id>
<journal-id journal-id-type="publisher-id">IN</journal-id>
<journal-title-group>
<journal-title>Immune Network</journal-title>
</journal-title-group>
<issn pub-type="ppub">1598-2629</issn>
<issn pub-type="epub">2092-6685</issn>
<publisher>
<publisher-name>The Korean Association of Immunologists</publisher-name>
</publisher>
</journal-meta>

<article-meta>
<article-id pub-id-type="doi">10.4110/in.2005.5.3.172</article-id>
<article-categories>
<subj-group>
<subject>Original Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Enhanced CEA-specific Immune Responses by Tat-LLO Fusion Protein</article-title>
</title-group>

<contrib-group>

<contrib contrib-type="author">
<name>
<surname>Yi</surname>
<given-names>Soon-Aei</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>

<contrib contrib-type="author">
<name>
<surname>Sohn</surname>
<given-names>HyunJung</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>

<contrib contrib-type="author">
<name>
<surname>Kim</surname>
<given-names>Chang-Hyun</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>

<contrib contrib-type="author">
<name>
<surname>Park</surname>
<given-names>Mi-Young</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>

<contrib contrib-type="author">
<name>
<surname>Oh</surname>
<given-names>Seong-Taek</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>

<contrib contrib-type="author" corresp="yes">
<name>
<surname>Kim</surname>
<given-names>Tai-Gyu</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>

</contrib-group>

<aff id="A1"><label>1</label>Department of Microbiology and Immunology, College of Medicine, The Catholic University of Korea, Seoul, Korea.</aff>
<aff id="A2"><label>2</label>Department of Surgery, College of Medicine, The Catholic University of Korea, Seoul, Korea.</aff>

<author-notes>
<corresp>Corresponding Author (<email>kimtg@catholic.ac.kr</email>)
</corresp>
</author-notes>


<pub-date pub-type="ppub">
<month>09</month>
<year>2005</year>
</pub-date>
<pub-date pub-type="epub">
<day>30</day>
<month>09</month>
<year>2005</year>
</pub-date>
<volume>5</volume>
<issue>3</issue>
<fpage>172</fpage>
<lpage>178</lpage>

<permissions>
<copyright-statement>Copyright &#x00A9; 2005 The Korean Association of Immunologists</copyright-statement>
<copyright-year>2005</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
<license-p>This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
</license>
</permissions>

<abstract>
<sec>
<title>Background</title>
<p>Carcinoembryonic antigen (CEA) is well-known soluble tumor marker frequently detectable in peripheral blood of carcinoma patients and considered as good target for antigen-specific immunotherapy. However, it is known that the induction of immune response to CEA is very difficult because CEA is a self-antigen expressed in fetal cells and weakly expressed in normal colorectal epithelial cells. To enhance anti-tumor immunity specific for CEA, recombinant CEA protein was modified using listeriolysin O (LLO) for endosomal lysis and transactivator of transcription (Tat) domain for transducing extracellular proteins into cytoplasm.</p>
</sec>
<sec>
<title>Methods</title>
<p>After immunization using dendritic cells pulsed with Tat-CEA, both Tat-CEA and LLO, and both Tat-CEA and Tat-LLO, antibody titer to CEA and LLO, cytotoxic T lymphocyte activity and the frequency of IFN-&#x03B3; producing T lymphocytes were measured.</p>
</sec>
<sec>
<title>Results</title>
<p>Immunization using DC pulsed with both Tat-CEA and Tat-LLO protein showed the increasement of production of CEA-specific antibody in serum, cytotoxic T lymphocyte activity, the frequency of IFN-&#x03B3; secreting T cells, compared with DC pulsed with both Tat-CEA and LLO. Furthermore the ratio of CD8<sup>+</sup> T cell to CD4<sup>+</sup> T cell among CEA-specific T cells was increased in group pulsed with both Tat-CEA and Tat-LLO.</p>
</sec>
<sec>
<title>Conclusion</title>
<p>These results suggested that DC vaccine using Tat-LLO could be used for the development of effective immunotherapy for the treatment of tumor.</p>
</sec>
</abstract>

<kwd-group>
<kwd>Carcinoembryonic antigen (CEA)</kwd>
<kwd>listeriolysin O (LLO)</kwd>
<kwd>transactivator of transcription (Tat)</kwd>
<kwd>dendritic cell (DC)</kwd>
<kwd>cytotoxic T lymphocyte (CTL)</kwd>
</kwd-group>

</article-meta>
</front>

</article>


